Colleen B Delaney

US Patent:

20130095079, Apr 18, 2013

Filed:

Apr 11, 2011

Appl. No.:

13/640297

Inventors:

Irwin D. Bernstein - Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

FRED HUTCHINSON CANCER RESEARCH CENTER - Seattle WA

International Classification:

A61K 35/48
G06F 19/00

US Classification:

424 937, 435372, 707758

Abstract:

The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

US Patent:

20130095080, Apr 18, 2013

Filed:

Apr 11, 2011

Appl. No.:

13/640298

Inventors:

Irwin D. Bernstein - Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Reserach Center - Seattle WA

International Classification:

A61K 35/48
G06F 19/22

US Classification:

424 937, 435372, 707758

Abstract:

The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/pro-genitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

US Patent:

8455250, Jun 4, 2013

Filed:

Dec 28, 2006

Appl. No.:

11/648824

Inventors:

Mohammad Heidaran - Chatham NJ, US
Jia-Lun Wang - Cherry Hill NJ, US
Qian Ye - Livingston NJ, US
Andrew Zeitlin - Basking Ridge NJ, US
Colleen Suzanne Delaney - Seattle WA, US

Assignee:

Anthrogenesis Corporation - Warren NJ

International Classification:

C12N 5/02

US Classification:

435373, 435325, 435366, 435372

Abstract:

The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e. g. , umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

US Patent:

20220218759, Jul 14, 2022

Filed:

May 15, 2020

Appl. No.:

17/611829

Inventors:

- Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Deverra Therapeutics Inc. - Seattle WA

International Classification:

A61K 35/51
A61P 35/02
A61K 35/28
A61K 31/7068
A61K 31/65
A61K 31/704
A61K 31/7076
A61K 38/19
A61K 31/7048
A61K 31/136
C12N 5/0775

Abstract:

The present invention relates to methods and compositions for treating a hematological malignancy with an expanded hematopoietic stem cell product in combination with a chemotherapy regimen.

US Patent:

20230017590, Jan 19, 2023

Filed:

Nov 27, 2020

Appl. No.:

17/780370

Inventors:

- Seattle WA, US
Devikha Chandrasekaran - Seattle WA, US
Mary Prieve - Lake Forest Park WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Deverra Therapeutics Inc. - Seattle WA

International Classification:

C12N 5/00
C12N 5/0789

Abstract:

The present disclosure provides compositions and methods for culturing hematopoietic stem and progenitor cells, while maintaining or increasing the subpopulation of hematopoietic stem cells (HSCs). The methods and compositions describe us a 3D zwitterionic hydrogel to provide a biocompatible culture microenvironment for culturing encapsulated hematopoietic stem and progenitor cells.

US Patent:

20200030384, Jan 30, 2020

Filed:

Oct 1, 2019

Appl. No.:

16/590255

Inventors:

- Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

A61K 35/51
C12N 5/0789
A61K 35/28
A61K 35/50
G16B 30/00

Abstract:

The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

US Patent:

20200009194, Jan 9, 2020

Filed:

Jan 24, 2018

Appl. No.:

16/480481

Inventors:

- Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

A61K 35/28
C12N 5/0789

Abstract:

Systems and methods to expand hematopoietic stem cell (HSC) using zwitterionic hydrogels (ZTG) are described. Expansion using the disclosed systems and methods results in HSC populations with (i) an increased proportion of HSC versus partially or fully differentiated cells, (ii) proportionally lower cell surface expression levels of differentiation/maturation markers, (iii) reduced metabolic rates following expansion, and/or (iv) a greater proportion of quiescent cells following expansion, as compared to currently available clinical expansion methods.

US Patent:

20190298777, Oct 3, 2019

Filed:

Apr 8, 2019

Appl. No.:

16/378206

Inventors:

- Seattle WA, US
Colleen Delaney - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

A61K 35/51
C12N 5/0789
A61K 35/50

Abstract:

The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.